Quantum-Si Inc
Business
Quantum-Si Incorporated develops and sells proprietary single-molecule detection instruments for next-generation protein sequencing (NGPS), including the Platinum and Platinum Pro platforms. The company provides consumable kits for library preparation, barcoding, and sequencing, along with analysis software. Quantum-Si distributes products globally through direct sales in the United States, combined direct and distributor channels in Europe, and distributors in international markets, serving academic research institutions, biopharmaceutical companies, CDMOs, and government entities for research applications.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 2 | 3 | 1 | 0 | 0 | |
| Cost of revenue | 1 | 1 | 594,000 | 0 | 0 | |
| Gross profit | 1 | 2 | 488,000 | 0 | 0 | |
| Research and development | 54 | 60 | 67 | 72 | 47 | |
| Selling, general and administrative | 45 | 51 | 45 | 42 | 50 | |
| Lease termination expense, net | 14 | 0 | 0 | — | — | |
| Legal settlement expense, net of insurance proceeds | 5 | 0 | 0 | — | — | |
| Total operating expenses | 117 | 110 | 112 | 124 | 97 | |
| Loss from operations | −116 | −109 | −111 | −124 | −97 | |
| Dividend income | 697,000 | 2 | 9 | 5 | 3 | |
| Interest income | 9 | 10 | 459,000 | — | — | |
| Unrealized gain on trading securities | 0 | 0 | 11 | −16 | — | |
| Realized loss on trading securities | 0 | 0 | −5 | −4 | — | |
| Change in fair value of warrant liabilities | 4 | −4 | −300,000 | 6 | 4 | |
| Other income (expense), net | 955,000 | −19,000 | 366,000 | 458,000 | 19,000 | |
| Loss before provision for income taxes | −101 | −101 | −96 | −132 | −95 | |
| Provision for income taxes | −58,000 | −56,000 | 0 | 0 | 0 | |
| Net loss | −101 | −101 | −96 | −132 | −95 | |
| Basic net loss per share (in dollars per share) | −0.51 | −0.71 | −0.68 | −0.95 | −1.19 | |
| Diluted net loss per share (in dollars per share) | −0.51 | −0.71 | −0.68 | −0.95 | −1.19 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders, basic (in shares) | 198 | 143 | 141 | 139 | 80 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted (in shares) | 198 | 143 | 141 | 139 | 80 | |
| Net unrealized (loss) gain on marketable securities, net of tax | −63,000 | 70,000 | 0 | 0 | — | |
| Foreign currency translation adjustment | 12,000 | −25,000 | 0 | 0 | — | |
| Total other comprehensive (loss) gain, net of tax | −51,000 | 45,000 | 0 | 0 | — | |
| Comprehensive loss | −101 | −101 | −96 | −132 | −95 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 22 | 49 | 134 | 84 | 36 | |
| Marketable securities, current | 141 | 160 | — | — | — | |
| Accounts receivable, net of allowance of $270 and $124, respectively | 561,000 | 1 | 368,000 | 0 | — | |
| Legal settlement insurance receivable | 5 | 0 | — | — | — | |
| Inventory | 3 | 4 | 4 | 0 | — | |
| Prepaid expenses and other current assets | 5 | 3 | 4 | 7 | 6 | |
| Total current assets | 176 | 218 | 266 | 358 | 477 | |
| Marketable securities, non-current | 53 | 0 | — | — | — | |
| Property and equipment, net | 13 | 16 | 16 | 17 | 9 | |
| Operating lease right-of-use assets | 3 | 13 | 14 | 16 | 7 | |
| Other assets | 234,000 | 808,000 | 695,000 | 697,000 | 690,000 | |
| Total assets | 246 | 248 | 298 | 391 | 503 | |
| Accounts payable | 2 | 2 | 2 | 4 | 3 | |
| Accrued payroll and payroll-related costs | 6 | 5 | 5 | 6 | — | |
| Accrued contracted services | 3 | 2 | 2 | 4 | — | |
| Accrued legal settlement liability | 8 | 0 | — | — | — | |
| Accrued expenses and other current liabilities | 2 | 5 | 2 | 1 | 7 | |
| Warrant liabilities, current | 794,000 | 0 | — | — | — | |
| Current portion of operating lease liabilities | 2 | 4 | 2 | 1 | 859,000 | |
| Total current liabilities | 23 | 18 | 12 | 16 | 12 | |
| Warrant liabilities, non-current | 0 | 5 | 1 | 1 | 7 | |
| Operating lease liabilities | 2 | 9 | 14 | 16 | 7 | |
| Other long-term liabilities | 34,000 | 19,000 | 11,000 | 0 | 206,000 | |
| Total liabilities | 25 | 32 | 27 | 33 | 26 | |
| Commitments and contingencies (Note 17) | — | — | — | — | — | |
| Additional paid-in capital | 918 | 812 | 767 | 758 | 744 | |
| Accumulated other comprehensive (loss) income | −6,000 | 45,000 | 0 | — | — | |
| Accumulated deficit | −698 | −597 | −496 | −400 | −267 | |
| Total stockholders equity | 220 | 215 | 272 | 359 | 477 | |
| Total liabilities and stockholders equity | 246 | 248 | 298 | 391 | 503 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 4 | 5 | 4 | 3 | 1 | |
| Allowance for credit losses | 146,000 | 124,000 | 0 | 0 | — | |
| Non-cash lease expense | 2 | 2 | 1 | 1 | 415,000 | |
| Loss on lease termination | 2 | 0 | 0 | — | — | |
| Write-off of construction on process due to lease termination | 1 | 0 | 0 | — | — | |
| Accretion on marketable securities | −8 | −8 | 0 | 0 | — | |
| Loss on disposal of fixed assets | 31,000 | 425,000 | 136,000 | 91,000 | 70,000 | |
| Write-down of inventory | 2 | −3 | −3 | 0 | — | |
| Change in fair value of warrant liabilities | −4 | 4 | 278,000 | −6 | −4 | |
| Change in fair value of contingent consideration | 0 | 0 | −400,000 | 176,000 | 36,000 | |
| Stock-based compensation | 11 | 9 | 9 | 11 | 25 | |
| Other | −1,000 | 22,000 | 0 | 0 | — | |
| Accounts receivable, net | 626,000 | −1 | −368,000 | 0 | 0 | |
| Legal settlement insurance receivable | −5 | 0 | 0 | — | — | |
| Inventory | −2 | 4 | 286,000 | 0 | 0 | |
| Prepaid expenses and other current assets | −2 | 486,000 | 2 | −1 | −5 | |
| Operating lease right-of-use assets | 0 | 0 | −83,000 | −10 | −7 | |
| Other assets | 3,000 | −113,000 | 2,000 | −7,000 | −690,000 | |
| Accounts payable | −338,000 | 390,000 | −1 | 721,000 | 709,000 | |
| Accrued expenses and other current liabilities | −1 | 4 | −2 | 4 | 4 | |
| Accrued legal settlement liability | 8 | 0 | 0 | — | — | |
| Other long-term liabilities | 14,000 | 7,000 | 7,000 | 0 | 0 | |
| Operating lease liabilities | −3 | −3 | −2 | 9 | 8 | |
| Net cash used in operating activities | −95 | −88 | −94 | −91 | −67 | |
| Purchases of property and equipment | −3 | −5 | −5 | −11 | −6 | |
| Internally developed software - capitalized costs | 0 | −59,000 | −763,000 | 0 | 0 | |
| Purchases of marketable securities | −405 | −369 | −124 | −834,000 | −441 | |
| Sales and maturities of marketable securities | 379 | 341 | 273 | 149 | 0 | |
| Net cash (used in) provided by investing activities | −28 | −33 | 143 | 137 | −451 | |
| Proceeds from exercise of stock options | 2 | 1 | 357,000 | 3 | 6 | |
| Proceeds from vesting of restricted stock | 1,000 | 1,000 | 0 | 0 | — | |
| Proceeds from issuance of common stock from direct equity offerings and the exercise of public and pre-funded warrants, net of fees and issuance costs | 94 | 0 | 0 | — | — | |
| Proceeds from issuance of common stock from at-the-market offering, net of commissions and issuance costs | 0 | 35 | 0 | 0 | — | |
| Deferred offering costs | 0 | 0 | −208,000 | 0 | −4,000 | |
| Refund of issuance costs | 0 | 14,000 | 0 | 0 | — | |
| Net cash provided by financing activities | 95 | 36 | 149,000 | 2 | 517 | |
| Effect of exchange rate changes on cash and cash equivalents | 12,000 | −25,000 | 0 | 0 | — | |
| Net (decrease) increase in cash and cash equivalents | −28 | −85 | 50 | 49 | — | |
| Cash received from exchange of research and development tax credits | 2 | 0 | 2 | 0 | 173,000 | |
| Cash paid for taxes | 24,000 | 0 | 0 | — | — | |
| Property and equipment purchased but not paid | 217,000 | 337,000 | 302,000 | 1 | 1 | |
| Transfers from inventory to property and equipment | 1 | 0 | 0 | — | — | |
| Deferred offering costs payable | 0 | 553,000 | 105,000 | 0 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Quantum-Si Inc's CIK number?
Quantum-Si Inc's SEC CIK number is 0001816431 (1816431). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Quantum-Si Inc's SEC filings?
All of Quantum-Si Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Quantum-Si Inc last report earnings?
Quantum-Si Inc (QSI) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001816431-26-000032). This is Quantum-Si Inc's most recent earnings filing of record — not a forecast of its next earnings date.
What is Quantum-Si Inc's most recent earnings 8-K?
Quantum-Si Inc's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001816431-26-000032. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Quantum-Si Inc's latest earnings 8-K →
Look up any company's CIK number →